What you need to know about closed-loop systems for the management of diabetes, from real-world data to expanding indications, access, implementation, and limitations.
An overview of the revised European Medicines Agency guideline on the clinical investigation of medicinal products for the treatment or prevention of type 1 and 2 diabetes.
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with diabetes. This case in an older adult with type 1 diabetes shows how EIAS can be managed in an outpatient setting.
Once-weekly insulins offer a way to simplify therapy and reduce the treatment burden for people with type 2 diabetes, and also have potential for individuals with type 1 diabetes.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with diabetes. This case in an older adult with type 1 diabetes shows how EIAS can be managed in an outpatient setting.
Intermittently scanning CGM detected hypoglycemia in a woman previously diagnosed with schizophrenia and treated with antipsychotic medication. Insulinoma was diagnosed and resected, resolving her neuropsychiatric symptoms.
This case indicates that capillary blood glucose monitoring should be used alongside intermittently scanned CGM when pregnancy is complicated by type 1 diabetes and CKD.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Health state utility values provide a quantitative indication of the extent to which a particular disease, complication or treatment-related side effect influences the quality of life (QoL) of an individual. Utility values quantify QoL on a scale …
The worldwide prevalence of type 1 diabetes mellitus (T1DM) is growing, including in women in reproductive age [ 1 ]. Consequently, pregnancies complicated by maternal diabetes are becoming an increasing concern. The interplay between maternal …
In the late 90s, sodium-glucose cotransporter type 2 (SGLT2) inhibitors were developed as non-insulin-dependent antidiabetic drugs, and were eventually approved by the Food and Drug Administration and the European Medicines Agency between 2012 and …
Early initiation of intensive insulin therapy has been demonstrated to be effective in controlling glycemia and possibly preserving beta-cell function. Innovations in insulin formulations and delivery systems continue. However, we have seen an …
An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Hypoglycaemia impacts the health and wellbeing of people with diabetes [ 1 – 3 ], which can be subjectively quantified using patient-reported outcome measures (PROMs). Valid and reliable PROMs are vital for accurately assessing real-life health …
Health state utility values provide a quantitative indication of the extent to which a particular disease, complication or treatment-related side effect influences the quality of life (QoL) of an individual. Utility values quantify QoL on a scale …
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have dramatically changed the treatment strategy of patients with type 2 diabetes (T2D) following the completion of several seminal clinical trials, including EMPA-REG OUTCOME (Empagliflozin …
Current treatment guidelines for type 2 diabetes mellitus (T2DM) currently recommend the use of incretin-based therapies as first-line injectable treatment, but many people with T2DM will require insulin at some point during the course of their …
